Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Clot-Busting catheter shows promise in leg vein blockages

NCT ID NCT07027878

Disease control Sponsor: Abbott Medical Devices Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well the JETi device works in real-world settings to remove blood clots from deep leg veins (venous thrombosis). The device uses suction and tiny water jets to break up and remove clots. In 121 patients, the device successfully cleared at least 75% of the clot in most cases, with few serious complications like bleeding or re-clotting within 30 days. The results suggest the JETi system is a safe and effective tool for treating acute and subacute leg vein clots.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JETi System (a catheter device that uses suction and saline jets to break up and remove blood clots)
What this could lead to
If successful, this registry could confirm that the JETi device is a safe and effective tool for quickly clearing blood clots from deep leg veins, potentially reducing long-term complications like swelling or pain.
What could go wrong
This is an observational registry, not a randomized trial, so results may be influenced by patient selection. The study is also relatively small (121 participants) and lacks a comparison group, making it hard to prove the device is better than other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

121 people

The number who actually took part.

Started

Aug 2020

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects of all genders from the patient population undergoing percutaneous treatment of thrombosis in the peripheral vascular system will be enrolled in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject was treated or is expected to be treated for acute/subacute thrombosis, as determined by the investigator, in the peripheral vasculature with the JETi Hydrodynamic Thrombectomy System. 2. Subject or legally authorized representative must provide written informed consent. 3. Subject must be ≥ 18 years of age. Exclusion Criteria: 1. Subject has previously been registered in the JETi Registry in the last 12 months unless treated in the contralateral limb/different anatomy; patients treated in the contralateral limb/different anatomy within the last 12 months may re-enroll in the study. 2. Subject is currently participating in another drug or device clinical investigation. 3. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the past 20 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral venous thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thrombophilia due to thrombin defect venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thrombosis

Contacts and locations

Locations

  • Arkansas Heart Hospital

    Little Rock, Arkansas, 72211, United States

  • Ascension St. John Jane Phillips

    Bartlesville, Oklahoma, 74006, United States

  • Cedars Sinai Medical Center

    Los Angeles, California, 90095, United States

  • Charleston Area Medical Center

    Charleston, West Virginia, 25304, United States

  • ClinRé

    Thornton, Colorado, 80023, United States

  • Evangelisches Krankenhaus Königin Elisabeth Herzberge

    Berlin, 10365, Germany

  • Hendrick Medical Center

    Abilene, Texas, 79601, United States

  • Henry Ford Detroit

    Detroit, Michigan, 48202, United States

  • Hightower Clinical

    Oklahoma City, Oklahoma, 73102, United States

  • HonorHealth

    Scottsdale, Arizona, 85258, United States

  • Hôpital Saint-François d'Assise

    Québec, Quebec, G1L 3L5, Canada

  • Klinikum Hochsauerland

    Arnsberg, 59759, Germany

  • Marien Hospital Herne

    Herne, North Rhine-Westphalia, 44625, Germany

  • Medizinische Einrichtungen der Universität zu Köln

    Cologne, 50937, Germany

  • Midwest Cardiovascular Research Foundation

    Davenport, Iowa, 52803, United States

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • PIH Good Samaritan

    Los Angeles, California, 90017, United States

  • Royal Perth Hospital

    Perth, 6000, Australia

  • Sankt Gertrauden Krankenhaus

    Berlin, 10713, Germany

  • Southoast Hospital

    Fall River, Massachusetts, 02740, United States

  • St. Luke's Hospital

    Kansas City, Missouri, 64111, United States

  • St. Mary Medical Center

    Hobart, Indiana, 46342, United States

  • Stanford University Hospital and Clinics

    Palo Alto, California, 94305, United States

  • University Hospital Aachen

    Aachen, North Rhine-Westphalia, 52074, Germany

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44195, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Louisville

    Louisville, Kentucky, 40202, United States

  • University of Utah Hospital

    Salt Lake City, Utah, 84132, United States

  • Universitätsklinikum Giessen

    Giessen, 35392, Germany

  • Weill Cornell Medicine

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.